Rikke L. Ratzer

Copenhagen, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Are exercise booster sessions effective at preserving exercise-induced effects in people with multiple sclerosis? A randomised controlled trial: results from the MSBOOST trial.

Are exercise booster sessions effective at preserving exercise-induced effects in people with multiple sclerosis? A randomised controlled trial: results from the MSBOOST trial.

Journal: Journal of science and medicine in sport

Published: August 28, 2025

Profiling the Cerebrospinal Fluid Proteome in Progressive Multiple Sclerosis: Treatment Effects and Associations with IgM Oligoclonal Bands.

Profiling the Cerebrospinal Fluid Proteome in Progressive Multiple Sclerosis: Treatment Effects and Associations with IgM Oligoclonal Bands.

Journal: Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology

Published: April 10, 2025

Chitinase-1 in cerebrospinal fluid and white matter injury in patients with progressive multiple sclerosis.

Chitinase-1 in cerebrospinal fluid and white matter injury in patients with progressive multiple sclerosis.

Journal: Journal of neuroimmunology

Published: December 03, 2024

Study protocol: effects of exercise booster sessions on preservation of exercise-induced adaptations in persons with multiple sclerosis, a multicentre randomised controlled trial-the MS BOOSTER trial.

Study protocol: effects of exercise booster sessions on preservation of exercise-induced adaptations in persons with multiple sclerosis, a multicentre randomised controlled trial-the MS BOOSTER trial.

Journal: BMJ open

Published: August 17, 2024

Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study.

Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study.

Journal: Multiple sclerosis and related disorders

Published: March 01, 2023

NfL and GFAP in serum are associated with microstructural brain damage in progressive multiple sclerosis.

NfL and GFAP in serum are associated with microstructural brain damage in progressive multiple sclerosis.

Journal: Multiple sclerosis and related disorders

Published: January 03, 2023

Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.

Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.

Journal: Multiple sclerosis and related disorders

Published: November 07, 2022

GPR15+ T cells are Th17 like, increased in smokers and associated with multiple sclerosis.

GPR15+ T cells are Th17 like, increased in smokers and associated with multiple sclerosis.

Journal: Journal of autoimmunity

Published: June 30, 2018

CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.

CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: May 19, 2018

Disability in progressive MS is associated with T2 lesion changes.

Disability in progressive MS is associated with T2 lesion changes.

Journal: Multiple sclerosis and related disorders

Published: September 21, 2017

Defining active progressive multiple sclerosis.

Defining active progressive multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: August 24, 2017

Characterization of naïve, memory and effector T cells in progressive multiple sclerosis.

Characterization of naïve, memory and effector T cells in progressive multiple sclerosis.

Journal: Journal of neuroimmunology

Published: March 23, 2017

Showing 1-12 of 25

Last Updated: 09/26/2026